Apremilast
- Generic Name
- Apremilast
- Brand Names
- Otezla, Apremilast Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O7S
- CAS Number
- 608141-41-9
- Unique Ingredient Identifier
- UP7QBP99PN
- Background
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the tr...
- Indication
Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Active Psoriatic arthritis, Ulceration of the mouth
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06586112
- Locations
- 🇺🇸
Exalt Clinical Research, Chula Vista, California, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Marvel Clinical Research, LLC, Huntington Beach, California, United States
A Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06588738
- Locations
- 🇨🇦
CCA Medical Research Corp, Ajax, Ontario, Canada
🇨🇦SKiN Health, Cobourg, Ontario, Canada
🇨🇦Kingsway Clinical Research, Etobicoke, Ontario, Canada
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06382987
- Locations
- 🇯🇵
Mebix. Inc., Minato-ku, Tokyo, Japan
🇯🇵Fukuoka University Hospital, Fukuoka, Japan
Apremilast for Alcohol Use Disorder Treatment in Women and Men
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT06324435
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus
- Conditions
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-02-15
- Target Recruit Count
- 64
- Registration Number
- NCT06260904
- Locations
- 🇮🇳
AIIMS Bhubaneswar, Bhubaneswar, Odisha, India
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT06122649
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1108
- Registration Number
- NCT06108544
- Locations
- 🇺🇸
Advanced Medical Research, PC, Atlanta, Georgia, United States
🇨🇦Skinsense Medical Research - 411 2nd Ave N - Probity - PPDS, Saskatoon, Saskatchewan, Canada
🇵🇱ETG Siedlce - PPDS, Siedlce, Mazowieckie, Poland
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT06088199
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Affiliated Dermatology, Scottsdale, Arizona, United States
🇺🇸Clear Dermatology, Scottsdale, Arizona, United States
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 693
- Registration Number
- NCT06088043
- Locations
- 🇺🇸
Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona, United States
🇺🇸First OC Dermatology - Fountain Valley, Fountain Valley, California, United States
🇺🇸Center for Dermatology Clinical Research, Fremont, California, United States
Apremilast for Erythema Multiforme
- Conditions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Robert Micheletti
- Target Recruit Count
- 8
- Registration Number
- NCT05875714
- Locations
- 🇺🇸
Perelman Center For Advanced Medicine, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.